These emerging ICs are playing an increasingly pivotal role in the treatment of HNSCC, providing additional therapeutic targets that may circumvent resistance to PD-1/PD-L1 and CTLA-4 inhibitors and enhance the therapeutic efficacy. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.